Authors:
Tiffany R. Hodges1, Nader Sanai4, Joanne Xiu5, Lyndon Kim6, Shouhao Zhou2, Santosh Kesari7, Marta Penas-Prado3, Amy Heimberger1
Abstract
BACKGROUND: Medulloblastoma, an aggressive but potentially curable CNS disease, remains a treatment challenge due to the biological heterogeneity of the disease. Analysis of actionable targets can provide opportunities in the development of curative therapies. To identify potential candidate genes, we investigated alterations in a cohort of medulloblastoma patients.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |